sábado, 31 de marzo de 2018

Press Announcements > FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse

Press Announcements > FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse









The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved remission after initial treatment for this type of ALL, the presence of MRD means they have an increased risk of relapse.Continue reading.

No hay comentarios:

Publicar un comentario